These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 35388357)

  • 21. A concise review of the changing landscape of hepatocellular carcinoma.
    Draper A
    Am J Manag Care; 2020 Oct; 26(10 Suppl):S211-S219. PubMed ID: 33052638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic Treatment for Advanced Hepatocellular Carcinoma.
    Bouattour M; Mehta N; He AR; Cohen EI; Nault JC
    Liver Cancer; 2019 Oct; 8(5):341-358. PubMed ID: 31768344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic Treatment Options in Hepatocellular Carcinoma.
    Rimassa L; Pressiani T; Merle P
    Liver Cancer; 2019 Nov; 8(6):427-446. PubMed ID: 31799201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocellular carcinoma, novel therapies on the horizon.
    El Dika I; Makki I; Abou-Alfa GK
    Chin Clin Oncol; 2021 Feb; 10(1):12. PubMed ID: 32527116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment.
    Kim BH; Park JW
    J Liver Cancer; 2021 Sep; 21(2):124-138. PubMed ID: 37383078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolving therapeutic strategies for advanced hepatocellular carcinoma.
    Qureshi A; Michel M; Lerner J; Dasanu CA
    Expert Opin Pharmacother; 2021 Dec; 22(18):2495-2506. PubMed ID: 34252328
    [No Abstract]   [Full Text] [Related]  

  • 28. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets.
    Luo XY; Wu KM; He XX
    J Exp Clin Cancer Res; 2021 May; 40(1):172. PubMed ID: 34006331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?
    Mahipal A; Tella SH; Kommalapati A; Lim A; Kim R
    Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31366113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence.
    De Luca E; Marino D; Di Maio M
    Cancer Manag Res; 2020; 12():3721-3729. PubMed ID: 32547208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes.
    Zhang CH; Li M; Lin YP; Gao Q
    Curr Gene Ther; 2020; 20(2):84-99. PubMed ID: 32600231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma.
    Lee MMP; Chan LL; Chan SL
    J Liver Cancer; 2023 Sep; 23(2):262-271. PubMed ID: 37589044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatocellular Carcinoma: Beyond the Border of Advanced Stage Therapy.
    Zarlashat Y; Abbas S; Ghaffar A
    Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities.
    Laface C; Fedele P; Maselli FM; Ambrogio F; Foti C; Molinari P; Ammendola M; Lioce M; Ranieri G
    Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36011021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current statuses of molecular targeted and immune checkpoint therapies in hepatocellular carcinoma.
    Kong D; Liu C; Miao X; Wang Y; Ding X; Gong W
    Am J Cancer Res; 2020; 10(5):1522-1533. PubMed ID: 32509395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials.
    Pan Y; Wang R; Hu D; Xie W; Fu Y; Hou J; Xu L; Zhang Y; Chen M; Zhou Z
    Front Biosci (Landmark Ed); 2021 Oct; 26(10):873-881. PubMed ID: 34719212
    [No Abstract]   [Full Text] [Related]  

  • 37. The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.
    Liu L; Qin S; Zhang Y
    Target Oncol; 2021 Mar; 16(2):153-163. PubMed ID: 33528759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
    Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
    Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.